Cowen

Bevi is a manufacturer of smart water dispensers designed for offices and commercial spaces. Their innovative product offers customizable flavors created from filtered tap water and natural ingredients, allowing users to make personalized drinks. Bevi's dispensers provide nutritional information and enable users to track their environmental impact, promoting eco-friendly hydration. By eliminating the need for bottled beverages, Bevi aims to reduce waste associated with production, shipping, and disposal. The company envisions a future in which their platform transforms beverage delivery by utilizing the municipal water supply.

PolySign is a company that specializes in developing secure and scalable infrastructure for financial institutions to effectively manage and trade digital assets. Its institutional-grade asset custody platform supports a wide range of digital assets, providing custodial and infrastructure solutions that cater to asset managers and exchanges. By integrating with existing financial organizations and global markets, PolySign aims to facilitate seamless trading while adhering to the highest regulatory standards. The company focuses on delivering secure, global, multi-currency facilities that empower its clients to fully capitalize on the opportunities presented by digital assets.

Portico Capital is the leading investment bank exclusively serving the Information and Business Services/Software industry. They have offices in the US and UK and have represented companies throughout the world.

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Digital Prime Technologies specializes in customizable prime brokerage technology solutions for financial institutions. The company develops a comprehensive platform that enables brokers and capital markets firms to facilitate trading and investing in digital assets. Its user-friendly interface integrates both API and SaaS offerings, allowing clients to connect with a diverse network of liquidity providers for transactions, borrowing, and lending of digital assets, as well as collateral management. This platform empowers clients to consolidate their preferred service providers, including custodians and liquidity partners, into a single, unified system.

AlphaSense, Inc. is a market intelligence platform that specializes in information discovery for research professionals. Founded in 2007 and headquartered in New York, the company has additional offices in London, Helsinki, Pune, and other locations. Its web-based platform aggregates and indexes financially relevant data from various sources, enabling users to conduct natural language searches for critical insights across filings, research, news, and other disclosures. The platform is designed to facilitate informed decision-making by providing users with the ability to set alerts, analyze data, and navigate complex information efficiently. AlphaSense serves nearly 2,000 enterprise clients, including a significant number of financial institutions and a majority of the S&P 500, who rely on its tools to drive their business decisions.

Quip NYC, Inc., operating as quip, is an oral healthcare company based in Brooklyn, New York, founded in 2014. The company designs, manufactures, and sells a range of oral care products, including electric toothbrushes, toothpastes, refillable floss pick and string, as well as various supplies such as toothbrush heads and travel covers. Quip is notable for being a pioneer in the direct-to-consumer oral care subscription model, providing customers with fresh supplies delivered every three months. In addition to its product offerings, quip also delivers oral care advice and is developing a technology platform to connect users with a network of dental professionals. Through its online platform, quip aims to make oral health simpler, more accessible, and enjoyable for consumers.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through a network of automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, California, ecoATM simplifies the process of selling unwanted electronics by offering consumers cash on the spot for their devices. The kiosks evaluate the worth of these used items, transforming them into valuable materials such as copper, silver, gold, or palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing the customer experience with both online and kiosk options for trading in pre-owned electronics. Positioned in high-traffic areas like malls and grocery stores, ecoATM kiosks provide a convenient, safe, and efficient means for consumers to engage in responsible recycling while receiving immediate compensation for their used devices. Additionally, Gazelle.com offers certified pre-owned devices, providing consumers with quality options at competitive prices.

PolySign is a company that specializes in developing secure and scalable infrastructure for financial institutions to effectively manage and trade digital assets. Its institutional-grade asset custody platform supports a wide range of digital assets, providing custodial and infrastructure solutions that cater to asset managers and exchanges. By integrating with existing financial organizations and global markets, PolySign aims to facilitate seamless trading while adhering to the highest regulatory standards. The company focuses on delivering secure, global, multi-currency facilities that empower its clients to fully capitalize on the opportunities presented by digital assets.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Proterra Inc. is a manufacturer of zero-emission electric buses, primarily focused on providing sustainable transportation solutions for public and commercial transit. Founded in 2004 and headquartered in Burlingame, California, with additional offices in Greenville, South Carolina, and City of Industry, California, Proterra designs its products, including 35-foot and 40-foot electric buses, to meet the diverse needs of urban and regional transit routes. The company's Catalyst platform is noted for its modularity, allowing it to adapt to various operational demands while delivering high energy efficiency. Proterra also offers a broad range of services, including vehicle electrification solutions, fleet planning, charging infrastructure, and comprehensive vehicle maintenance programs. By facilitating the transition away from fossil fuels, Proterra aims to enhance environmental quality and reduce operational costs for fleet operators, contributing to significant reductions in greenhouse gas emissions.

Kyber Data Science LLC is a subsidiary of Cowen Inc. focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through a network of automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, California, ecoATM simplifies the process of selling unwanted electronics by offering consumers cash on the spot for their devices. The kiosks evaluate the worth of these used items, transforming them into valuable materials such as copper, silver, gold, or palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing the customer experience with both online and kiosk options for trading in pre-owned electronics. Positioned in high-traffic areas like malls and grocery stores, ecoATM kiosks provide a convenient, safe, and efficient means for consumers to engage in responsible recycling while receiving immediate compensation for their used devices. Additionally, Gazelle.com offers certified pre-owned devices, providing consumers with quality options at competitive prices.

Cowen Inc. is a financial services firm that provides a range of investment banking, research, sales and trading, prime brokerage, and global clearing services both in the United States and internationally. Established in 1918 and headquartered in New York, the company operates through two segments: Operating Company and Asset Company. It specializes in public and private capital raising, strategic advisory services, and mergers and acquisitions for a diverse clientele, including middle-market companies and institutional investors. Cowen trades various financial instruments, including common stocks and equity-linked securities, and offers comprehensive prime brokerage services. Additionally, the firm provides research and investment products tailored to institutional and private clients, covering sectors such as healthcare, technology, consumer, energy, and biotechnology. Cowen is also engaged in private investments and legacy investment activities, demonstrating a commitment to serving a broad spectrum of financial needs.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

ConvergEx is a technology firm that specializes in providing essential software products and technology-enabled services to a broad range of clients, totaling over 6,000 across 100 markets. Its diverse clientele primarily consists of asset managers and financial intermediaries, which includes investment advisors, hedge funds, mutual funds, plan sponsors, trust banks, family offices, separately managed accounts, broker-dealers, exchanges, alternative trading systems, and investment banks. ConvergEx's offerings are designed to support the critical operational needs of these financial entities, enabling them to enhance their performance and efficiency in a competitive landscape.

CEFC China Energy Company Limited is a private collective enterprise primarily engaged in energy and financial services. The company focuses on investing in oil and gas development and operates various subsidiaries that manage oil and gas terminals, including refineries and gas stations. CEFC China aims to enhance international economic cooperation in the energy sector while also working to establish a structured international investment bank and investment group. Through its diversified operations, CEFC China seeks to strengthen its presence in the global energy market.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Quarton Partners, based in Birmingham, Michigan, was a middle market investment banking firm that provided services to privately held and publicly traded companies, as well as private equity firms. The firm specialized in mergers and acquisitions, corporate sales, divestitures, equity and debt capital raising, restructuring, recapitalizations, and complex securities transactions. Quarton Partners focused on various industries, including business services, consumer products, distribution, healthcare, and industrial manufacturing. The firm's principals completed numerous engagements across the U.S. and globally, establishing a strong reputation in the investment banking sector. In December 2015, Quarton Partners merged with Blue Corporate Finance to create Quarton International.

Blue Corporate Finance, founded in 2001 and based in Munich, Germany, was a prominent independent advisory firm specializing in corporate finance for mid-sized transactions in Europe. The firm provided expert guidance to entrepreneurs, companies, and investors on various financial matters, including mergers and acquisitions, management buyouts, capital raising, and restructuring. Throughout its operation, Blue Corporate Finance successfully advised 180 clients on transactions totaling over 4 billion euros. In 2015, the firm merged with Quarton Partners, resulting in the formation of Quarton International, thereby expanding its reach and capabilities in the financial advisory sector.

Conifer Securities is a company that was acquired by Cowen Group in 2015

Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.

Maxwell Technologies specializes in the development, manufacturing, and marketing of energy storage and power delivery solutions. Its products cater to various sectors, including automotive, heavy transportation, renewable energy, backup power, wireless communications, and industrial and consumer electronics. The company is known for producing ultra-high-voltage capacitors, as well as truck and generator starting capacitors, which are designed to deliver cost-effective, energy-efficient, and environmentally friendly performance. Maxwell Technologies aims to ensure failure-free operation throughout the lifespan of its products, even in the most demanding applications, and also develops radiation-hardened microelectronic components and systems for satellites and spacecraft.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Echo Global Logistics is a prominent provider of technology-enabled transportation and supply chain management services. The company specializes in offering multimodal shipping options and asset-light third-party logistics services, including intermodal and international air and ocean freight forwarding. By leveraging proprietary web-based technology, dedicated service teams, and strong procurement capabilities, Echo Global Logistics helps clients achieve significant transportation savings while delivering high-quality service. This focus on efficiency and competitive pricing positions the company as a valuable partner in addressing clients' logistics needs.

Seabridge Gold Inc. is a development-stage company focused on the acquisition and exploration of gold properties primarily in North America. The company boasts one of the largest resources of gold, copper, and silver globally, with key projects including the Kerr-Sulphurets-Mitchell property in British Columbia, the Courageous Lake property in the Northwest Territories, and the 3 Aces Project in Yukon. Seabridge aims to enhance shareholder value by increasing resource and reserve ownership per share through a systematic approach: acquiring deposits, expanding them via exploration, converting them into reserves through engineering, and potentially partnering with established producers for mine construction. The company is committed to environmental stewardship and community engagement, striving to minimize its ecological impact while supporting local communities.

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to discovering and developing personalized therapies for unmet medical needs in oncology. The company focuses on small molecule cancer therapeutics, with a pipeline that includes APTO-253, currently in a Phase 1b trial for patients with relapsed/refractory blood cancers such as acute myeloid leukemia and high-risk myelodysplastic syndrome. Additionally, Aptose is collaborating with CrystalGenomics, Inc. on CG026806, which is in a Phase 1a/b trial for relapsed/refractory acute myeloid leukemia and various B-cell malignancies. Another partnership with OHM Oncology involves the development and commercialization of APL-581 for the treatment of hematologic malignancies. Founded in 1986 and headquartered in Toronto, Canada, Aptose Biosciences was previously known as Lorus Therapeutics Inc. and changed its name in August 2014.

Sunworks is focused on advancing solar technology through the development of innovative 3-dimensional solar cell designs. This approach aims to enhance the conversion efficiency of sunlight into electricity, addressing the significant losses associated with conventional solar cells, which can reflect up to 30% of incident sunlight and lose more within the material itself. By employing light management techniques inspired by fiber optic technology, these next-generation solar cells are engineered to trap sunlight within micro-photovoltaic structures, allowing photons to bounce until converted into electrons. The anticipated result is a solar cell that operates with greater efficiency, consequently reducing the cost per watt and making solar energy more accessible and affordable for a broader audience.

InterDigital Communications, LLC, based in King of Prussia, Pennsylvania, specializes in designing and developing advanced digital wireless technology solutions. As a subsidiary of InterDigital, Inc., the company focuses on research and development in areas such as wireless communications, video, and artificial intelligence. InterDigital's technologies facilitate connected and immersive experiences across various communications and entertainment products and services. The company's revenue primarily derives from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, InterDigital operates in multiple regions, including the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority of its revenue sourced from China.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

GlassesOff is a health care technology company based in Hod Hasharon, HaMerkaz, that specializes in developing consumer-oriented software applications aimed at enhancing near vision sharpness. Founded in 2007, the company has created a non-invasive solution for individuals suffering from presbyopia, enabling them to reduce their reliance on reading glasses. Utilizing its proprietary technology platform, GlassesOff offers a personalized program that monitors users' performance and progress in addressing symptoms such as blurred near vision, eye fatigue, headaches, and slow reading. The software employs exercises designed to improve the image processing function in the visual cortex of the brain, thereby enhancing users' reading capabilities without altering the optical characteristics of the eye.

Dahlman Rose & Company, LLC was a research-driven investment bank that specialized in the transportation, infrastructure, and natural resources sectors of the global supply chain. Founded in 2004 and headquartered in New York, the firm provided a range of services including institutional sales and trading, equity and fixed income research, mergers and acquisitions advisory, and underwriting. Dahlman Rose had a strong focus on sector specialization, particularly in areas such as marine shipping, offshore services, oil and gas exploration and production, oilfield services, and various modes of freight transport. The firm also maintained offices in Boston, Houston, and San Francisco, serving clients both domestically and internationally. In 2013, Dahlman Rose was acquired by Cowen Group, Inc.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an oral, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer in combination therapies. In addition to tucatinib, Cascadian Therapeutics is advancing its preclinical pipeline, which includes CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborative agreements with Array BioPharma for tucatinib development, Sentinel Oncology for novel Chk1 inhibitors, and Adimab for discovering new antibodies targeting immunotherapy in oncology. Founded in 1985 and formerly known as Oncothyreon Inc., Cascadian Therapeutics continues to focus on providing targeted therapies that aim to improve cancer treatment outcomes.

Aurora Flight Sciences, based in Manassas, Virginia, specializes in the design and manufacture of aerospace vehicles for both commercial and military applications. The company operates production facilities in Bridgeport, West Virginia, and Columbus, Mississippi, along with a Research and Development Center in Cambridge, Massachusetts. Aurora focuses on developing unmanned systems and high-altitude, long-endurance autonomous aircraft. It also innovates in various fields, including aircraft configurations, autonomous systems, propulsion technologies, and manufacturing processes. By applying advanced technologies and materials, Aurora aims to enhance the future of flight for government and commercial airline customers.

Reef is a provider of internet software applications for the management of e-business.

Nextest Systems Corporation, founded in 1997, specializes in the design and manufacture of automatic test equipment (ATE) for non-volatile memory, microcontrollers, ASICs, and system-on-a-chip (SOC) semiconductors. The company focuses on providing cost-effective solutions that enhance throughput, reliability, functionality, and capacity for manufacturers, all while minimizing testing costs and expediting time to market. With a workforce of around 150 employees and sales and support offices located globally, Nextest has established a significant presence in the testing equipment industry, having shipped over 1,000 systems worldwide since its inception.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

SiberCore Technologies Incorporated is a pure-play, Internet IC company developing high-value-added Application Specific Standard Products (ASSPs) for intelligent hardware-based switching and routing platforms, such as Gigabit / Terabit Routers and Layer 2 / 3 / 4 Ethernet Switches. The company's initial products are a family of high-speed high-capacity packet forwarding engines based on Content Addressable Memories (CAM technology) which overcome the performance bottleneck associated with the network's routing table look-up function. This emerging market has been created by the demands of the explosion in datacom traffic, coupled with the worldwide deployment of fiber optics and DWDM. These broadband deployments have shifted the bottleneck from the Access and Transport section of the network, to the Routers and Switches connecting to these pipes. The company's founding technical team gained industry-wide recognition for its world-class design expertise in this area at Nortel Networks. A veteran Executive team in all the functional divisions of the company supplements this preeminent technical team.

TelOptica was funded in 1999 by communications network experts in optical, next-generation network design engineering and in operations research and algorithm development. The TelOptica team today includes highly regarded technologists with experience from established telco giants such as MCI and Sprint, international original equipment manufacturers such as Alcatel / DSC, Nortel, and IBM, and management consulting firms including McKinsey and Associates and Carreker Corporation. TelOptica is a well-funded, fast growing, privately held, optical communications technology company. TelOptica incorporated in Texas , received initial funding and support from the Startech business incubator of Richardson, Texas, and closed on its second round of funding from Trellis Partners, Austin Ventures, Centerpoint Ventures, SSM Ventures of Austin, and SG Cowen in June 2001.

The company provides enterprise portal software for the deployment and management of Intranet and extranet portals. The company's Coreport enterprise portal software allows businesses to provide all their stakeholders with a single, secure point of unified and personalized access to content, applications, processes, and services from any wired or wireless device.

ThoughtWorks, Inc. is a global technology consultancy that specializes in software delivery, tools, and consulting services aimed at helping organizations achieve their ambitious goals. Founded in 1993 and headquartered in Chicago, Illinois, the company offers a range of solutions, including Mingle for project management, Go for continuous delivery, Snap for cloud deployment, and Twist for test automation. ThoughtWorks integrates strategy, design, and software engineering to support organizations in commercial, social, and government sectors as they navigate digital transformation. Its service lines encompass enterprise modernization, platforms and cloud, customer experience, product and design, data and artificial intelligence, and digital transformation operations. The company operates in multiple regions, generating significant revenue from North America while maintaining a presence in Asia-Pacific, Europe, and Latin America.

With more than 15 million page-views and more than 700,000 unique users per month, IPO.COM is the leading Internet provider of content and services to investors interested in initial public offerings, private placements and emerging growth companies. The company provides comprehensive IPO content including offering summaries, up-to-date pricing and filings, searchable EDGAR documents, daily columns and free weekly e-mail newsletters through the company's interactive portal and more than 150 financial web sites. Privately held, IPO.COM has offices in New York, Pennsylvania and California.

Tripod is a web publishing service based in Williamstown, Massachusetts, that enables users to create fully functional websites using professional templates and powerful plugins. The company provides a range of tools designed to simplify the website development process, allowing clients to easily build sites tailored to their needs. In addition to its core offerings, Tripod also provides value-added services, including Search Engine Optimization, theme development by professional web designers, and plugin development. Furthermore, seasoned engineers offer site migration services, ensuring that users can effectively transition their existing websites to the Tripod platform.